Dmitrii N. Zemskov

Dmitrii N. Zemskov

Auto-generated profile, based on publicly available information

Dmitrii N. Zemskov

National Research Ogarev Mordovia State University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2022 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
LBL. A. Balykova
L. A. Balykova
NSN. M. Selezneva
N. M. Selezneva
EGE. I. Gorshenina
E. I. Gorshenina
OSO. I. Shepeleva
O. I. Shepeleva
NKN. V. Kirichenko
N. V. Kirichenko
ПБП. А. Белый
П. А. Белый
The article presents the data from an open, two-stage, multicenter study on the efficacy and safety evaluation of a combined drug (a fixed combination of nirmatrelvir 300 mg and ritonavir 100 mg) in the complex therapy in COVID-19 patients.The aim of the study was to assess the safety, tolerability and pharmacokinetic parameters of the fixed combination of nirmatrelvir 300 mg and ritonavir 100 mg in healthy volunteers, the efficacy and safety assessment of the drug in the combination therapy compared with the standard therapy in COVID-19 patients.Material and methods. An open two-stage multicenter clinical study to assess the main pharmacokinetic parameters, safety, and efficacy against COVID-19 of the drug nirmatrelvir 300 mg and ritonavir 100 mg combination (Skyvira® PROMOMED RUS LLC, Russia) in the adult population, included 2 stages. At stage 1, safety, tolerability and pharmacokinetic parameters were evaluated in healthy volunteers (over 18 years of age) in order to confirm their comparability with the literature data known for a set of active substances. Phase 2 assessed efficacy and safety in COVID-19 patients. As a part of the second stage, the study involved 264 patients (men and women aged 18 to 80 years), who had been divided into two groups. The first group patients (n=132) received the study drugs (nirmatrelvir 300 mg and ritonavir 100 mg) – 1 tablet twice a day with an interval of 12±2 hours for 5 days in combination with pathogenetic and symptomatic therapy. The second group patients (n=132) received standard therapy in accordance with the approved Temporary Guidelines for the Prevention and Treatment of Novel Coronavirus Infection (Version 15 dated February 22, 2022).Results. During the study, none of the patients from the (nirmatrelvir + ritonavir) group experienced a transition of the COVID-19 course to a heavier severity level, in contrast to the patients in the standard therapy group. The study participants included patients with comorbidities (68% of the general population), with risk factors for COVID-19 progression to a heavier severity level and the risk of hospitalization (75% of the general population). There were no cases of COVID-19 progression to a heavier severity level in the study drug group. By the 6th day, in the nirmatrelvir + ritonavir group, the proportion of the patients who had achieved a complete recovery was twice more and amounted to 35.61% (p=0.0001), and the proportion of the patients with a negative RNA analysis to SARS-CoV-2 was 20% higher than in the comparison group, and amounted to 82.58% (p=0.0001). The fixed nirmatrelvir + ritonavir combination therapy has a favorable safety profile comparable to the standard therapy. The identified adverse reactions were transient in nature and did not require discontinuation of therapy or changes in the treatment regimen.Conclusion. The fixed nirmatrelvir + ritonavir combination has a favorable safety profile in COVID-19 patients, comparable to the standard therapy. The data obtained demonstrate a clinical and pharmacoeconomic feasibility of including the fixed (nirmatrelvir + ritonavir) combination in the COVID-19 treatment regimen.

15 December 2022 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
DZD. N. Zemskov
D. N. Zemskov
LBL. A. Balykova
L. A. Balykova
OROlga Radaev
Olga Radaev
KZK. Ya. Zaslavskaya
K. Ya. Zaslavskaya
ПБП. А. Белый
П. А. Белый
KKK. N. Koryanova
K. N. Koryanova
Since the beginning of the pandemic, repeated attempts have been made to develop etiotropic therapy for a novel coronavirus infection. Hydroxychloroquine, lopinavir/ritonavir, etc. derivatives were used as antiviral agents, however, they demonstrated a low efficiency and an insufficient safety. In this connection, other groups of drugs with a more effective and safe pharmacological profile are currently being actively used.The aimof the study was to analyze the literature references on the efficacy and safety of antiviral drugs for the COVID-19 treatment.Materials and methods.When searching for the materials for the review article writing, such abstract databases as PubMed, Google Scholar, e-Library were used. The search was carried out on publications for the period from January 2020 to september 2022. The key queries were: COVID-19, etiotropic therapy; immunological drugs; antiviral drugs; interferons.Results.Currently, there are various degrees of effective etiotropic drugs for the treatment of COVID-19 patients. The review has considered a few groups of drugs that are of interest from the point of view of etiotropic therapy: immunological drugs (anticovid plasma, the drugs based on antiviral antibodies, the drugs of recombinant interferons-α2 and -β1, as well as interferon inducers, i.e., the drugs based on double-stranded RNA sodium salt, and others); drugs that block the penetration of the virus into the cell (umifenovir); the drugs that disrupt the process of the viral replication (favipiravir, remdesivir, molnupiravir, nirmatrelvir/ritonavir).Conclusion.Synthetic antivirals, in particular favipiravir, molnupiravir, remdesivir, and nirmatrelvir/ritonavir, have the largest evidence base for their efficacy and safety. The search for new effective and safe etiotropic drugs for the treatment of COVID-19, as well as the collection and analysis of post-registration data on the drugs already used in clinical practice, continues.

22 June 2023 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NPNatalia Pshenichnaya
Natalia Pshenichnaya
KOKhadizhat G. Omarova
Khadizhat G. Omarova
LBLarisa A. Balykova
Larisa A. Balykova
KZKira Y. Zaslavskaya
Kira Y. Zaslavskaya
DZDmitry N. Zemskov
Dmitry N. Zemskov
ПЮПшеничная Наталья Юрьевна
Пшеничная Наталья Юрьевна
Background: One of the basic principles for the treatment of COVID-19 patients is the early initiation of etiotropic therapy. The evidence base for assessment of the efficacy and safety of antivirals for COVID-19 continues to expand with new clinical trials. One of the promising etiotropic medications is molnupiravir. Aim: To evaluate the efficacy and safety of molnupiravir (Esperavir) in outpatients with COVID-19. Materials and methods: This randomized comparative open-label clinical study was conducted from December 1, 2021 to March 11, 2022 in 12 research centers in the Russian Federation. The study involved 240 outpatients with mild and moderate COVID-19. The mean age of patients was 43.5 years; 70,0% (168/240) of the patients had comorbidities, mainly obesity grade II and arterial hypertension. The outpatients were treated with molnupiravir (Esperavir, PROMOMED RUS LLC, Russia) in 4 capsules 200 mg twice daily (every 12 hours), with the single dose being 800 mg and the daily dose 1600 mg. Duration of treatment was 5 days. The patients were followed up for 28 days. The patients in the standard treatment group (n = 120) received antiviral therapy recommended for outpatients by the provisional guidelines effective at the time of the study. Pathogenetic and symptomatic therapy in both groups was comparable. Results: The results of the clinical study in 240 outpatients with mild or moderate COVID-19 showed that molnupiravir at a dose of 800 mg twice daily for 5 days significantly reduced (by 4-hold at days 1415 of the follow-up) the risk of disease progression to more severe course, compared with the standard therapy group (2.5% (3/120) and 10.0% (12/120) of patients; p = 0.0149.) By days 67 of the follow-up, the virus had been eliminated in 71.67% of the patients treated with the study drug and only in 58.3% (70/120) of the patients in the standard therapy group. Complete clinical recovery at days 67 was achieved in 19.2% (23/120) of the patients in the molnupiravir group, compared to 5.8% (7/120) in the standard therapy group. Compared to the standard therapy, treatment with molnupiravir also significantly reduced the frequency and severity of the disease symptoms, such as cough and change in odor or taste perception over the last 24 hours, already at 67 days after the start of treatment. Molnupiravir treatment was well tolerated, most adverse events were mild. There were no cases of drug withdrawal or dose modification of the study drug due to adverse events. Conclusion: The results of the clinical study of antiviral agent molnupiravir (Esperavir) have proven its benefits over standard therapy in outpatients with mild and moderate COVID-19 in terms of the disease worsening risk reduction and hospitalization, the rate of viral elimination, the changes in symptoms severity over time, improvement of the patients general status and clinical condition and reduction of COVID-19 complications both in patients without and with risk factors for severe COVID-19 outcomes. The results of this study demonstrated a favorable safety profile of molnupiravir in COVID-19 patients.

1 January 2022 in Infekcionnye bolezni
Verified
Journal Article
Closed access
KOKh.G. Omarova
Kh.G. Omarova
LBL.A. Balykova
L.A. Balykova
NPNatalia Pshenichnaya
Natalia Pshenichnaya
DZD.N. Zemskov
D.N. Zemskov
KZK.Ya. Zaslavskaya
K.Ya. Zaslavskaya
PBP.A. Belyy
P.A. Belyy
The aim of this study was to analyze the efficacy and safety of using etiotropic therapy with favipiravir and molnupiravir that can selectively bind and inhibit not only SARS-CoV-2 proteins but also other RNA-containing pathogens of acute respiratory diseases. High transmission of pathogens, the risk of becoming chronic, frequent complications, cases of co-infection with several pathogens, which can lead to a more severe course of the disease, insufficient vaccination effectiveness, all this requires additional strategies for both prevention and treatment of acute respiratory viral infections. RNA-dependent RNA polymerase (RdRp), which has no equivalent in human cells, is involved in RNA synthesis and is an excellent therapeutic target for diseases caused by RNA viruses, including SARS-CoV-2. The long process of drug development and the “reuse” of drugs approved for other indications or successfully tested in terms of safety and tolerability pose the challenge of rapid establishment of an effective drug, including for the treatment of severe cases of COVID-19. Key words: COVID-19, SARS-CoV-2, RNA-dependent RNA polymerase (RdRp), favipiravir, molnupiravir

25 September 2023 in Acta medica Eurasica
Verified
Journal Article
Closed access
LBLarisa A. Balykova
Larisa A. Balykova
NPNatalia Pshenichnaya
Natalia Pshenichnaya
KOKhadizhat G. Omarova
Khadizhat G. Omarova
DPDmitrii Yu. Pushkar
Dmitrii Yu. Pushkar
KZKira Ya. Zaslavskaia
Kira Ya. Zaslavskaia
ESElena V. Semenova
Elena V. Semenova
The aim of the study was to evaluate the efficacy and tolerability of the drug Molnupiravir in adult outpatients with mild Covid–19. Materials and methods. A randomized comparative open clinical trial of Molnupiravir (800 mg twice daily for 5 days in addition to symptomatic/pathogenetic therapy) was conducted in confirmed COVID-19 in comparison with a standard therapy. 240 patients (average age – 43.5 years; 70% had risk factors) were randomized in a 1:1 ratio to the Molnupiravir group and the standard therapy group. Clinical efficacy was assessed based on the analysis of the patient's daily diary, physical examination data and SARS-CoV-2 RNA in the smear from the oropharynx and nasopharynx. The primary endpoint was the proportion of patients with the transition of COVID-19 course to a more severe degree relative to the initial state 2 weeks after the onset of the disease. Significance was assessed using a two-sided version of the Fisher Exact test. Results. Molnupiravir: a) reduced the risk of disease progression by 4 times by the 14th –15th day of follow-up, compared with the risk in the control group (2.5% and 10% of patients, respectively, p = 0.0149); b) accelerated virus elimination by the 6th – 7th day of follow-up (71.67% vs. 58.33%, respectively); c) accelerated clinical recovery (which by day 6-7 had 19% of patients in the Molnupiravir group, and 6% of patients on standard therapy); d) reduced the frequency and severity of COVID-19 symptoms: cough, ageusia. The incidence of adverse events in the study participants was comparable. Conclusions. Molnupiravir administration reduces the risk of COVID-19 progression to a severe course, reduces the severity of COVID-19 clinical manifestations, probably by accelerating the virus elimination. The data obtained indicate feasibility of using Molnupiravir for COVID-19 treatment on an outpatient basis.